News and features
Read the latest news and features about our world-leading research, discoveries, fundraising and philanthropy. If you want to keep updated on our news, you can follow us on social media or sign up for our Search newsletter.
If you’re a journalist and want to find out more, you can contact our media relations team.
ICR-discovered drug abiraterone shows success in earlier-stage prostate patients
A large-scale international trial of abiraterone acetate in patients with earlier-stage prostate cancer has been stopped early due its effectiveness, so those on the placebo arm could be offered the drug.
Targeted skin cancer drug launches in UK
A life-extending pill for advanced melanoma that The Institute of Cancer Research and The Royal Marsden Hospital helped develop is now available in the UK.
Antidepressant shows promise as cancer treatment
An antidepressant combined with a drug derived from vitamin A could be used to treat a common adult form of leukaemia, according to laboratory research led by a team at the ICR.
Study offers reassurance to leukaemia patients
A clinical trial into the most common form of adult leukaemia has established that patients taking an aggressive but effective drug combination can return to a normal quality of life once they complete treatment.
Hereditary breast cancer: genetic code unravelled
Scientists from the ICR's Breakthrough Breast Cancer Research Centre have become the first to fully sequence the DNA of two breast cancers caused by a faulty BRCA1 gene. Surprisingly, changes in the genetic code of the two tumours looked almost entirely different from one another.
Professor Ian Judson explores new research into the safety of chemotherapy during pregnancy
Finding out that you have cancer comes as a big shock to most people – but what if you are also pregnant? Do you delay treatment until the baby is born, carry on with treatment during pregnancy or have a termination? What impact does chemotherapy have on your unborn child?
Buzz grows around ICR-discovered drug
The discovery of a new type of cancer drug, a PI3K inhibitor, by scientists at The Institute of Cancer Research and collaborators is creating a stir in the cancer research community.
New MRI technique predicts treatment response for neuroendocrine cancer patients
Scientists at the ICR and The Royal Marsden have shown that a specialist type of MRI scan can be used to predict which patients will respond to a targeted radiotherapy and monitor response to treatment.
Hundreds more breast cancer patients should be tested for BRCA1 gene
Leading breast cancer experts are calling for women under 50 who are diagnosed with triple-negative breast cancer to be offered testing for faults in the BRCA1 gene, according to a report published in the British Journal of Cancer today.
Educating the Next Generation of Researchers at The Institute of Cancer Research
In the ICR’s mission to relieve suffering due to cancer, major strategies include both education and the furthering of knowledge through scientific advancement. The programme of postgraduate research and taught training at the ICR both reflects these strategies and forms part of a commitment to the current and future pursuit of excellence in the fight against cancer.
Report reveals year of research success
The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust have launched their Joint Annual Research Report for 2010/11, highlighting a year of significant achievements.
Prostate cancer drug shows impressive new Phase III trial results
Patients with advanced prostate cancer who were given a new type of hormonal treatment called MDV3100 lived an extra 4.8 months compared to men taking a placebo, according to the full analysis of a Phase III trial.
